E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10083059 |
E.1.2 | Term | Alexander disease |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of ION373 in improving or stabilizing gross motor function in patients with Alexander disease |
|
E.2.2 | Secondary objectives of the trial |
To further evaluate the efficacy of ION373 in improving or stabilizing disease manifestations across the full range of affected domains (gross and fine motor, communication, swallowing, autonomic and/or other gastrointestinal functions, nutritional/growth status) in patients with Alexander disease |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Clinical phenotype and brain imaging consistent with a diagnosis of Alexander disease
2.Documented genetic mutation in the GFAP gene
3.Aged ≥ 2 to 65 years old at the time of informed consent
4.Able and willing to meet all study requirements, including travel to Study Center, procedures, measurements and visits
5.Patients < 18 years old at Screening must have a trial partner (parent, caregiver or other)
|
|
E.4 | Principal exclusion criteria |
1.Clinically significant abnormalities in medical history or physical examination
2.Platelet count or any other clinically significant laboratory abnormalities that would render a patient unsuitable for inclusion
3.Any contraindication or unwillingness to undergo MRI
4.Treatment with another investigational drug, biological agent, or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer; concurrent participation in any other clinical study (including observational and non-interventional studies)
5.Previous treatment with an oligonucleotide (including small interfering ribonucleic acid [siRNA]) within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received
6.History of gene therapy or cell transplantation or any other experimental brain surgery
7.Obstructive hydrocephalus
8.Presence of a functional ventriculoperitoneal shunt for the drainage of CSF or an implanted CNS catheter
9.known brain or spinal disease that would interfere with the LP process, CSF circulation or safety assessment.
10.Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks prior to Screening or planned during the study
11.Have any other conditions, which, in the opinion of the Investigator would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percent change from Baseline to Week 61 in the 10MWT in patients who are in Stratum 1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121 |
|
E.5.2 | Secondary end point(s) |
Key Secondary Endpoints:
Change from Baseline to Week 61 or value at Week 61 for the following:
• Patients’ self-identified most bothersome symptom (based on a Likert scale for change; all patients)
• PedsQL Generic Core Scales (all patients)
• Patient Global Impression of Severity (PGIS; all patients)
• Patient Global Impression of Change (PGIC; all patients)
• Clinical Global Impression of Change (CGIC; all patients)
Other Secondary Endpoints:
Change from Baseline to Week 61 or value at Week 61 for the following:
• Gross Motor Function Measure-88, Dimensions C, D and E
(GMFM-88, Dimensions C-E; patients < 5 years old at Screening) or
10MWT (patients ≥ 5 years old at Screening)
• 9-Hole Peg Test (9HPT; patients ≥ 8 years old at Screening)
• Vineland-3 Motor Skills Domain (patients < 8 years old at Screening)
• PedsQL Gastrointestinal Symptoms Scales (all patients)
• Vineland-3 Adaptive Behavior Composite (ABC) Score (patients
< 18 years old at Screening)
• Composite Autonomic Symptom Score 31 (COMPASS-31; patients
≥ 18 years old at Screening)
• CSF GFAP levels (all patients)
• Clinical Global Impression of Severity (CGIS; all patients)
• Alexander Disease Patient Domain Impression of Severity
(AxD-PDIS; all patients)
•Alexander Disease Patient Domain Impression of Change (AxD-PDIC;
all patients)
• Body weight percentile (for patients < 18 years old at Screening) or
body weight (for patients ≥ 18 years old at Screening |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Canada |
Israel |
Italy |
Japan |
Netherlands |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |